An Open-Label Pilot Study of Risperidone in the Treatment of Methamphetamine Dependence
Clicks: 185
ID: 274002
2007
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
9.0
/100
30 views
30 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Psychopharmacological treatments for methamphetamine (MA) dependence have questionable efficacy. Open-label risperidone was eval uated in veterans seeking MA dependence treatment. Participants (N = 11) received four weeks of risperidone. They provided weekly self-reports of substance use, urine drug screens, and adverse effects. Neuropsychological assessments and psychiatric symptomatology (Brief Symptom Inventory; BSI) were measured at baseline and follow-up. The eight completers had an average risperidone dose of 3.6mg/day and decreased days of MA use during the trial from a mean of 13.0 (SD = 6.5) in the 30 days prior to starting risperidone to a mean of 0.125 (SD = 0.4; i = 5.7. p = .001). When measured over time, fine motor function (Grooved Peg Board Dominant Hand) was the only neuropsychological domain to improve significantly. No other domain changed significantly from baseline to follow-up among study completers. BSI data were converted to demographically corrected T-scores utilizing appropriate normative data (mean = 50, SD = 10). BSI somatization T-scores declined from a mean of 59.0 (SD = 8.4) to 51. 8(SD = 8.3; i = 2.7, p
| Reference Key |
saxon2007journalan
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Charles W. Meredith,Craig Jaffe,Elisia Yanasak,Monique Cherrier,Andrew J. Saxon;Charles W. Meredith;Craig Jaffe;Elisia Yanasak;Monique Cherrier;Andrew J. Saxon; |
| Journal | journal of psychoactive drugs |
| Year | 2007 |
| DOI |
10.1080/02791072.2007.10399875
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.